864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study
864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study
Languages of Item:
English
Abstract:
Empty abstract
Publication year:
2003
Authors:
Abratt, RP Brune, D Dimopoulos, MA Kliment, J Breza, J Selvaggi, P Beuzeboc, P Demkow, T Oudard, S